Patents by Inventor Julia C. Piasecki
Julia C. Piasecki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230134375Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.Type: ApplicationFiled: June 29, 2022Publication date: May 4, 2023Applicant: Seagen Inc.Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz
-
Publication number: 20230050440Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.Type: ApplicationFiled: June 10, 2022Publication date: February 16, 2023Applicant: Seagen Inc.Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
-
Patent number: 11401339Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.Type: GrantFiled: August 22, 2019Date of Patent: August 2, 2022Assignee: Seagen Inc.Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
-
Publication number: 20210269527Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.Type: ApplicationFiled: October 28, 2020Publication date: September 2, 2021Applicant: Seagen Inc.Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz
-
Publication number: 20200062859Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.Type: ApplicationFiled: August 22, 2019Publication date: February 27, 2020Applicant: Seattle Genetics, Inc.Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
-
Publication number: 20200040082Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.Type: ApplicationFiled: August 15, 2019Publication date: February 6, 2020Applicant: Seattle Genetics, Inc.Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz
-
Publication number: 20170022285Abstract: Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a variety of immunotherapy treatments, including treatment of various cancers and infections.Type: ApplicationFiled: October 10, 2016Publication date: January 26, 2017Applicant: AMGEN INC.Inventors: Courtney BEERS, Jason C. O'NEILL, Ian FOLTZ, Randall R. KETCHEM, Julia C. PIASECKI
-
Patent number: 9464139Abstract: Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a variety of immunotherapy treatments, including treatment of various cancers and infections.Type: GrantFiled: August 28, 2014Date of Patent: October 11, 2016Assignee: AMGEN INC.Inventors: Courtney Beers, Jason C. O'Neill, Ian Foltz, Randal R. Ketchem, Julia C. Piasecki
-
Publication number: 20150064204Abstract: Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a varienty of immunotherapy treatments, including treatment of various cancers and infections.Type: ApplicationFiled: August 28, 2014Publication date: March 5, 2015Inventors: Courtney BEERS, Jason C. O'NEILL, Ian FOLTZ, Randal R. KETCHEM, Julia C. PIASECKI
-
Publication number: 20110287001Abstract: The invention provides methods for inducing apoptosis, comprising treatment of a patient with a TNF? inhibitor as well as with an IAP inhibitor and a TRAIL receptor agonist. The methods ameliorate the risk of unwanted effects, thereby resulting in an improved therapeutic index for IAP inhibitors in combination with a TRAIL receptor agonist.Type: ApplicationFiled: August 5, 2009Publication date: November 24, 2011Applicants: TETRALOGIC PHARMACEUTICALS, AMGEN INC.Inventors: Pamela M. Holland, Julia C. Piasecki, Christopher A. Benetatos, Srinivas K. Chunduru, Mark A. McKinlay
